The new analyses described in this article were funded by the Medical Research Council (Grant G0801509). Additional funding was from the British Heart Foundation (Project Grant PG/05/91), Encysive Pharmaceuticals, and Pfizer. Dr Dhaun is supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS/13/30/29994)
The discovery of endothelin created a lot of enthusiasm and paved new therapeutic avenues for the tr...
Endothelin is tightly involved in the regulation of vascular and renal function in health and in dis...
Abstract Background The vasoconstricting peptide endothelin-1 (ET-1) is associated with endothelial ...
Since its discovery in 1988 the powerful vasoconstrictor endothelin-1 (ET-1) has been widely implic...
Introduction: Selective antagonists of Endothelin-1 receptors (ERA) have been tested in diabetic and...
The incidence and prevalence of chronic kidney disease (CKD), with diabetes and hypertension account...
PhDEndothelin-1 (ET-1), the potent vasoconstrictor peptide, is synthesised from the 212 amino acid p...
Introduction. Endothelin-1(ET-1) is an important regulator of kidney function in health and disease...
AbstractDiabetes and arterial hypertension continue to be the main causes of chronic renal failure i...
The burden of chronic kidney disease is increasing worldwide, largely due to the increasing global p...
Purpose of review To summarize new clinical findings of endothelin receptor antagonists (ERA) in var...
Cardiovascular disease (CVD) is highly prevalent in chronic kidney disease (CKD) patients. Whilst t...
Proteinuria is a hallmark of chronic kidney disease (CKD) and cardiovascular disease (CVD), and a go...
The vascular endothelium synthesizes and releases a rangeof vasodilators and vasoconstrictors that h...
These studies were supported by the Medical Research Council (UK) (Grant G0801509), Community Fund ...
The discovery of endothelin created a lot of enthusiasm and paved new therapeutic avenues for the tr...
Endothelin is tightly involved in the regulation of vascular and renal function in health and in dis...
Abstract Background The vasoconstricting peptide endothelin-1 (ET-1) is associated with endothelial ...
Since its discovery in 1988 the powerful vasoconstrictor endothelin-1 (ET-1) has been widely implic...
Introduction: Selective antagonists of Endothelin-1 receptors (ERA) have been tested in diabetic and...
The incidence and prevalence of chronic kidney disease (CKD), with diabetes and hypertension account...
PhDEndothelin-1 (ET-1), the potent vasoconstrictor peptide, is synthesised from the 212 amino acid p...
Introduction. Endothelin-1(ET-1) is an important regulator of kidney function in health and disease...
AbstractDiabetes and arterial hypertension continue to be the main causes of chronic renal failure i...
The burden of chronic kidney disease is increasing worldwide, largely due to the increasing global p...
Purpose of review To summarize new clinical findings of endothelin receptor antagonists (ERA) in var...
Cardiovascular disease (CVD) is highly prevalent in chronic kidney disease (CKD) patients. Whilst t...
Proteinuria is a hallmark of chronic kidney disease (CKD) and cardiovascular disease (CVD), and a go...
The vascular endothelium synthesizes and releases a rangeof vasodilators and vasoconstrictors that h...
These studies were supported by the Medical Research Council (UK) (Grant G0801509), Community Fund ...
The discovery of endothelin created a lot of enthusiasm and paved new therapeutic avenues for the tr...
Endothelin is tightly involved in the regulation of vascular and renal function in health and in dis...
Abstract Background The vasoconstricting peptide endothelin-1 (ET-1) is associated with endothelial ...